Literature DB >> 30977574

Engineered Skin Tissue Equivalents for Product Evaluation and Therapeutic Applications.

Sana Suhail1,2, Naseem Sardashti1,2, Devina Jaiswal1,3, Swetha Rudraiah1,4, Manoj Misra5, Sangamesh G Kumbar1,2.   

Abstract

The current status of skin tissue equivalents that have emerged as relevant tools in commercial and therapeutic product development applications is reviewed. Due to the rise of animal welfare concerns, numerous companies have designed skin model alternatives to assess the efficacy of pharmaceutical, skincare, and cosmetic products in an in vitro setting, decreasing the dependency on such methods. Skin models have also made an impact in determining the root causes of skin diseases. When designing a skin model, there are various chemical and physical considerations that need to be considered to produce a biomimetic design. This includes designing a structure that mimics the structural characteristics and mechanical strength needed for tribological property measurement and toxicological testing. Recently, various commercial products have made significant progress towards achieving a native skin alternative. Further research involve the development of a functional bilayered model that mimics the constituent properties of the native epidermis and dermis. In this article, the skin models are divided into three categories: in vitro epidermal skin equivalents, in vitro full-thickness skin equivalents, and clinical skin equivalents. A description of skin model characteristics, testing methods, applications, and potential improvements is presented.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  commercial; cosmetic; pharmaceutical; product testing; skin; tribology

Mesh:

Year:  2019        PMID: 30977574      PMCID: PMC6615970          DOI: 10.1002/biot.201900022

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  91 in total

1.  Development of a highly sensitive in vitro phototoxicity assay using the SkinEthic reconstructed human epidermis.

Authors:  F X Bernard; C Barrault; A Deguercy; B De Wever; M Rosdy
Journal:  Cell Biol Toxicol       Date:  2000       Impact factor: 6.691

Review 2.  Hydrogels for tissue engineering.

Authors:  K Y Lee; D J Mooney
Journal:  Chem Rev       Date:  2001-07       Impact factor: 60.622

3.  Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts.

Authors:  E Dantzer; F M Braye
Journal:  Br J Plast Surg       Date:  2001-12

Review 4.  Tissue-engineered human living skin substitutes: development and clinical application.

Authors:  K H Lee
Journal:  Yonsei Med J       Date:  2000-12       Impact factor: 2.759

5.  Reconstructed skin equivalents for assessing percutaneous drug absorption from pharmaceutical formulations.

Authors:  N Zghoul; R Fuchs; C M Lehr; U F Schaefer
Journal:  ALTEX       Date:  2001       Impact factor: 6.043

6.  In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum.

Authors:  I Alberti; Y N Kalia; A Naik; J D Bonny; R H Guy
Journal:  J Control Release       Date:  2001-04-28       Impact factor: 9.776

7.  Predictivity of an in vitro model for acute and chronic skin irritation (SkinEthic) applied to the testing of topical vehicles.

Authors:  V Picarles; S Chibout; M Kolopp; J Medina; P Burtin; M E Ebelin; S Osborne; F K Mayer; A Spake; M Rosdy; B De Wever; R A Ettlin; A Cordier
Journal:  Cell Biol Toxicol       Date:  1999-04       Impact factor: 6.691

8.  Lipid and ultrastructural characterization of reconstructed skin models.

Authors:  M Ponec; E Boelsma; A Weerheim; A Mulder; J Bouwstra; M Mommaas
Journal:  Int J Pharm       Date:  2000-08-10       Impact factor: 5.875

9.  [Development of a new in vitro test for dermal phototoxicity using a model of reconstituted human epidermis]

Authors:  Manfred Liebsch; Christa Barrabas; Dieter Traue; Horst Spielmann
Journal:  ALTEX       Date:  1997       Impact factor: 6.043

10.  Effect of skin barrier competence on SLS and water-induced IL-1alpha expression.

Authors:  Susan Gibbs; Helene Vietsch; Ursi Meier; Maria Ponec
Journal:  Exp Dermatol       Date:  2002-06       Impact factor: 3.960

View more
  7 in total

1.  Small, Cationic Antifungal Proteins from Filamentous Fungi Inhibit Candida albicans Growth in 3D Skin Infection Models.

Authors:  Jeanett Holzknecht; Sandrine Dubrac; Sarah Hedtrich; László Galgóczy; Florentine Marx
Journal:  Microbiol Spectr       Date:  2022-05-02

Review 2.  3D skin models in domestic animals.

Authors:  Laurent Souci; Caroline Denesvre
Journal:  Vet Res       Date:  2021-02-15       Impact factor: 3.683

Review 3.  Many ways, one microorganism: Several approaches to study Malassezia in interactions with model hosts.

Authors:  Kevin Ehemann; María Juliana Mantilla; Felipe Mora-Restrepo; Andrea Rios-Navarro; Maritza Torres; Adriana Marcela Celis Ramírez
Journal:  PLoS Pathog       Date:  2022-09-08       Impact factor: 7.464

4.  Skin-on-a-chip models: General overview and future perspectives.

Authors:  I Risueño; L Valencia; J L Jorcano; D Velasco
Journal:  APL Bioeng       Date:  2021-07-08

5.  Polysaccharide-Based Bioink Formulation for 3D Bioprinting of an In Vitro Model of the Human Dermis.

Authors:  Tanja Zidarič; Marko Milojević; Lidija Gradišnik; Karin Stana Kleinschek; Uroš Maver; Tina Maver
Journal:  Nanomaterials (Basel)       Date:  2020-04-11       Impact factor: 5.076

Review 6.  Bioactive polymeric materials and electrical stimulation strategies for musculoskeletal tissue repair and regeneration.

Authors:  Bryan Ferrigno; Rosalie Bordett; Nithyadevi Duraisamy; Joshua Moskow; Michael R Arul; Swetha Rudraiah; Syam P Nukavarapu; Anthony T Vella; Sangamesh G Kumbar
Journal:  Bioact Mater       Date:  2020-04-07

Review 7.  Development of Skin-On-A-Chip Platforms for Different Utilizations: Factors to Be Considered.

Authors:  J Ponmozhi; S Dhinakaran; Zsófia Varga-Medveczky; Katalin Fónagy; Luca Anna Bors; Kristóf Iván; Franciska Erdő
Journal:  Micromachines (Basel)       Date:  2021-03-10       Impact factor: 2.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.